Skip to main content

Table 4 Comparison of serum antibody levels of HDs versus those of patients with chronic kidney disease (CKD)

From: Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke

Sample information HD Type-1 CKD Type-2 CKD Type-3 CKD
      Total sample number 82 145 32 123
      Male/female 44/38 106/39 21/11 70/53
      Age (average ± SD) 44.1 ± 11.2 66.0 ± 10.4 76.0 ± 9.8 62.0 ± 11.7
Alpha analysis (antibody level) DIDO1-Ab FOXJ2-Ab CPSF2-Ab  
HD Average 3166 1300 914  
SD 1423 517 298  
Cutoff value 6012 2334 1509  
Positive no. 6 3 3  
Positive rate (%) 7.3% 3.7% 3.7%  
Type 1-CKD Average 6805 2141 939  
SD 4675 1330 382  
Positive no. 63 41 7  
Positive rate (%) 43.4% 28.3% 4.8%  
P (vs HD) < 0.0001 < 0.0001 0.579  
Type 2-CKD Average 6693 2245 1020  
SD 3347 930 281  
Positive no. 12 11 2  
Positive rate (%) 37.5% 34.4% 6.3%  
P (vs HD) < 0.0001 < 0.0001 0.081  
Type 3-CKD Average 5264 1770 936  
SD 2161 829 421  
Positive no. 33 17 10  
Positive rate (%) 26.8% 13.8% 8.1%  
P (vs HD) < 0.0001 < 0.0001 0.656  
  1. CKD types 1, 2, and 3 correspond to diabetic kidney disease, nephrosclerosis, and glomerulonephritis, respectively. The upper panel indicates the numbers of all samples and samples from males and females as well as age (average ± SD). The lower panel summarizes the serum antibody levels examined by AlphaLISA using purified DIDO1-GST protein and synthetic bCPSF2 and bFOXJ2 peptides as antigens as described in the legend of Table 2. Box-whisker plots of the same results are shown in Fig. 4a, e, and i. P values lower than 0.05 and positive rates higher than 10% are marked in bold